Serum prothrombin conversion accelerator
Brand names,
Serum prothrombin conversion accelerator
Analogs
Serum prothrombin conversion accelerator
Brand Names Mixture
Serum prothrombin conversion accelerator
Chemical_Formula
C1972H3076N560O597S28
Serum prothrombin conversion accelerator
RX_link
http://www.rxlist.com/cgi/generic3/novoseven.htm
Serum prothrombin conversion accelerator
fda sheet
Serum prothrombin conversion accelerator
msds (material safety sheet)
Serum prothrombin conversion accelerator
Synthesis Reference
No information avaliable
Serum prothrombin conversion accelerator
Molecular Weight
45079.1
Serum prothrombin conversion accelerator
Melting Point
58 oC (Petersen, L.C. et al., Eur. J. Biochem 261: 124-129 (1999)).
Serum prothrombin conversion accelerator
H2O Solubility
No information avaliable
Serum prothrombin conversion accelerator
State
Liquid
Serum prothrombin conversion accelerator
LogP
-0.311
Serum prothrombin conversion accelerator
Dosage Forms
Solution (IV injection); Solution (IV infusion); Tablet; Powder for solution
Serum prothrombin conversion accelerator
Indication
For treatment of hemorrhagic complications in hemophilia A and B
Serum prothrombin conversion accelerator
Pharmacology
Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Serum prothrombin conversion accelerator
Absorption
No information avaliable
Serum prothrombin conversion accelerator
side effects and Toxicity
No information avaliable
Serum prothrombin conversion accelerator
Patient Information
No information avaliable
Serum prothrombin conversion accelerator
Organisms Affected
Humans and other mammals